The 2026 annual meeting of the Alzheimer’s Association is just a few weeks away. The 2026 Alzheimer’s Association International Conference (AAIC) is the world’s largest meeting of professionals dedicated to dementia science and clinical practice. This year, AAIC is set to run from July 12 through July 15, in London, United Kingdom. Registration for in-person and virtual attendance for members and non-members is still open.

Today's AAIC 2026 preview is a curated selection of sessions from each day of the conference, including all clinical toolbox and clinical pearl sessions. Session descriptions were not provided. All times and dates are accurate as of June 10, 2026. Consult the full AAIC planner for the most up-to-date information.

Key Sessions for Clinicians at the 2026 Alzheimer’s Association International Conference 

Sunday, July 12

  • Connecting the Drops: Trajectories and Novel Fluid Biomarkers in Early AD
    • 8:00 AM – 8:45 AM
  • Enabling the Tau Therapeutic Pipeline
    • 9:00 AM – 10:30 AM
  • Advances and Real-World Impact of Blood-Based Biomarkers
    • 9:00 AM – 10:30 AM
  • Welcome and Awards Plenary / Accelerating the Discovery and Developments of Medicines for Neurodegeneration
    • 11:00 AM – 12:15 PM
  • Supporting the Supporters: Global Evidence on Family Caregiving in Dementia
    • 2:00 PM – 3:30 PM
  • Timelines of Down Syndrome-Associated Alzheimer’s Disease to Advance Clinical Trials
    • 4:15 PM – 5:45 PM
  • Menopause as a Window of Alzheimer’s Disease Risk: Neurocognitive Pathways in Women
    • 4:15 PM – 5:45 PM

Monday, July 13

  • Emerging Interventions Across the Dementia Care Pathway
    • 8:00 AM – 8:45 AM
  • Normal Pressure Hydrocephalus: Emerging Research and Future Directions
    • 9:00 AM – 10:30 AM
  • Care-Based Approaches to Diagnosis, Eligibility, and Monitoring of Anti-Amyloid Therapies
    • 9:00 AM – 10:30 AM
  • Lifestyle Intervention and Brain Health: Insights from US POINTER Study
    • 9:00 AM – 10:30 AM
  • Eligibility for Anti-Amyloid Immunotherapy: Amyloid Biomarkers in the Real World / Understanding Dementia in Latin America: New Insights from the 10/66 Studies
    • 11:00 AM – 12:15 PM
  • Integrating Multimodal Biomarkers for Dementia Prognosis: From Research Into Clinical Care
    • 2:00 PM – 3:30 PM
  • Recent Tau Trials: Clinical, Biomarker, Preclinical Learnings and Next Generation Therapy
    • 2:00 PM – 3:30 PM
  • Developing Topics in Lifestyle Interventions
    • 4:15 PM – 5:45 PM

Tuesday, July 14

  • From Evidence to Practice: Implementing Alzheimer’s Association Clinical Guidance in Real World Care
    • 8:00 AM – 8:45 AM
  • Interpretation and Clinical Applicability of Blood Biomarkers of Alzheimer’s Disease Across Contexts, Settings, and Health Care Systems
    • 9:00 AM – 10:30 AM
  • Anti-Amyloid Therapy: Real World Experience
    • 9:00 AM – 10:30 AM
  • What’s Possible at Mealtimes: Restoring Person-Centered Eating and Swallowing Care in Dementia
    • 9:00 AM – 10:30 AM
  • From Curiosity to Cure: The Neprilysin-Donanemab & Amyloid Beta-Tau Axes in Alzheimer’s Disease / Proteomic Subtypes of AD: What Do They Mean and How Will They Influence or Benefit Drug Development for Alzheimer’s Disease?
    • 11:00 AM – 12:15 PM
  • Neuroimmune Targets for Neurodegenerative Diseases
    • 2:00 PM – 3:30 PM
  • Managing Neuropsychiatric Features Across Dementias
    • 2:00 PM – 3:30 PM
  • Applying the New Biological Frameworks for Neuronal Synucleinopathy: From Staging to Treatment
    • 2:00 PM – 3:30 PM
  • Anti-Amyloid Therapies for Alzheimer’s Disease: Challenges for Implementation in Different Countries and Health Systems
    • 4:15 PM – 5:45 PM

Wednesday, July 15

  • Dementia Diagnosis and Interventions at the Primary Care Level and Among Underrepresented Populations
    • 8:00 AM – 8:45 AM
  • Navigating Anti-Anyloid Therapy in Alzheimer’s Disease: Monitoring, Management and Maintenance
    • 9:00 AM – 10:30 AM
  • Dementia With Lewy Bodies: Clinical and Neuropathological Insights
    • 9:00 AM – 10:30 AM
  • Neuropsychiatric Manifestations of Alzheimer’s Disease and Other Dementia / Prevalence of Alzheimer’s Disease Pathology in the Community
    • 11:00 AM – 12:15 PM
  • The Use of Biomarkers in Clinical Practice
    • 2:00 PM – 3:30 PM
  • Beyond the Diagnosis: Multidisciplinary Management of LBD Across the Disease Continuum
    • 2:00 PM – 3:30 PM
  • Competing or Complementary? PET and Plasma Biomarkers in Research and Practice
    • 2:00 PM – 3:30 PM
  • Next-Generation Neuroimaging: Monitoring Treatments and Disease Progression
    • 2:00 PM – 3:30 PM
  • An Update on Imaging and Fluid Biomarkers in Lewy Body Dementia
    • 4:15 PM – 5:45 PM

Check out our other neurology-related content and be sure to sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.